Analysts await Genesis Healthcare, Inc. (NASDAQ:GEN) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $0.04 EPS, down 75% or $0.03 from last year’s $0.07 per share.

At the moment 8 analysts are watching Genesis Healthcare, Inc. (NASDAQ:GEN), 1 rate it “Buy”, 1 “Outperform”, 5 “Underperform”, 0 “Sell”, while 1 “Hold”.

Looking forward, for the quarter ending Jun-16, 5 analysts have a mean sales target of 1,440.76 million. For the quarter ending Sep-16, 5 analysts have a mean sales target of 1,442.33 million whilst for the year ending Dec-16, 6 analysts have a mean target of 5,766.62 million.

In terms of earnings per share, 6 analysts have a 0.08 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 6 analysts have a 0.06 EPS mean target and for the quarter ending Sep-16 there are 6 estimates of 0.24 EPS.

The biggest institutional shareholders in Genesis Healthcare, Inc. include HighTower Advisors, LLC which owns 4 million shares in the company valued at $15.15 million. Columbia Pacific Advisors, LLC is the second biggest holder with 3 million shares currently valued at 9.93 million whilst Invesco Canada Fund Inc has 2 million shares valued at 7.46 million.

Total shares held by institutions as of the most recent company filings are 21,961,158 with a reported 1,373,492 bought and 981,446 sold. These holdings make up 14.3% of the company’s outstanding shares.

Currently insiders hold 8,275,084 shares in the business which makes up 5.39% of shares. The biggest holder currently is George V. Hager,Jr who owns 1,267,780 shares (0.83% of those outstanding), whilst Mr. Steven Fishman holds 1,020,734 (0.66% of shares outstanding) and Jose Lynch holds 677,076 (0.44% of shares outstanding).

The stock decreased 0.80% or $0.02 during the last trading session, hitting $2.47. Genesis Healthcare, Inc. (NASDAQ:GEN) has fallen 80.97% over the past 6 months and is downtrending.